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Abstract: The molecular chaperone heat shock protein 90 (Hsp90) is a current inhibition target for
the treatment of diseases, including cancer. In humans, there are two major cytosolic isoforms of
Hsp90 (Hsp90α and Hsp90β). Hsp90α is inducible and Hsp90β is constitutively expressed. Most
Hsp90 inhibitors are pan-inhibitors that target both cytosolic isoforms of Hsp90. The development of
isoform-selective inhibitors of Hsp90 may enable better clinical outcomes. Herein, by using virtual
screening and binding studies, we report our work in the identification and characterisation of novel
isoform-selective ligands for the middle domain of Hsp90β. Our results pave the way for further
development of isoform-selective Hsp90 inhibitors.
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1. Introduction
Heat shock protein 90 (Hsp90) is a class of 90 kDa dimeric chaperone proteins from the heat
shock protein family [1–11]. Members of the Hsp90 family are highly conserved and can be found
in almost all organisms (except for archaea) [12–14]. The main function of Hsp90 is to maintain the
proper folding of proteins within the cell [1–11]. Its specific tasks include the assistance of folding of
the nascent polypeptide chains, the stabilisation of proteins (in particularly during heat shock or other
stress conditions), and catalysing the refolding of denatured proteins [1–11]. Due to the central role
Hsp90 plays in protein folding and stabilisation, the protein is involved in many important cellular
processes. These include (but are not limited to) the regulation of cellular homeostasis, cell cycle
control, signal transduction, and cytoprotection [1–11].
Structurally, each Hsp90 monomer comprises three domains [4,6,9–11], which are termed the
N-terminal domain (NTD), middle domain (MD), and C-terminal domain (CTD). The NTD is joined
with the MD through a flexible linker, which is named the charged region. The NTD binds and catalyses
the hydrolysis of adenosine triphosphate (ATP), which induces conformational change that is essential
to the chaperone function of Hsp90 [15,16]. The CTD contains the homodimerisation site [17,18], whilst
the MD is responsible for client protein binding [19,20]. The MD also modulates the ATPase activity
of the NTD through interactions with the γ-phosphate moiety of ATP [19,20]. The activity of Hsp90
is mediated by a number of co-chaperones [21,22]. All three domains are involved in the binding of
different co-chaperones [21,22].
In humans, there are two major cytosolic isoforms of Hsp90, which are Hsp90α and Hsp90β
(Table S1) [23]. There are inherent differences between the cellular processes that the two isoforms
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are involved in. Hsp90β is constitutively expressed and it is associated with long-term processes
such as cellular adaptation [23–26]. In contrast, Hsp90α is involved in processes that require fast
response, presumably because it is inducible and shows different client protein preferences under
stress conditions [23–27].
Hsp90 is a current inhibition target for the treatment of diseases including cancer. This can be
attributed to Hsp90’s ability to maintain and regulate oncoproteins [28,29], as well as those proteins
that aid the initiation and progression of tumours [5,30]. For example, overexpression of Hsp90α is
often found in acute and chronic tumours (but not benign tumours), and Hsp90β has been implied
in multidrug resistance in chronic tumours [23]. There is, therefore, a great anticipation towards the
development of Hsp90 inhibitors with cancer therapeutic potential. For example, the inhibition of
Hsp90 has been shown to lead to cell cycle arrest and apoptosis of cancerous cells [31]. The inhibition
of Hsp90 may also help overcome resistance in chemotherapy [32–34].
Numerous inhibitors of Hsp90 have been discovered in the last 15 years [35–47]. Most of them
target binding sites at the NTD and CTD. For example, geldanamycin [48,49], 17-N-allylamino-
17-demethoxygeldanamycin [50], and ganetespib (also known as STA-9090) [51,52] target the ATP
binding pocket at the NTD, and novobiocin was found to bind the CTD of Hsp90 [53]. In spite of
the discovery of numerous inhibitors that target the NTD and CTD, there are only few studies on the
inhibition of MD [54,55]. It is also worth noting that all 17 small molecule Hsp90 inhibitors that have
entered clinical trials to date target the NTD of both isoforms of Hsp90 [35–47]. Only a handful of
isoform-selective Hsp90 inhibitors have been reported [55–62].
We are interested in the development of novel Hsp90 inhibitors. In particular, the isoform-selective
Hsp90 inhibitors are of importance because they may give better clinical outcomes than pan-Hsp90
inhibitors [63–65]. In addition, isoform-selective inhibitors will also enable studies on the roles of the
different Hsp90 isoforms without resorting to genetic manipulations, which are often more invasive.
The MD of Hsp90 is of particular interest because the possibility exists to develop isoform-specific
Hsp90 binders [55,56] due to the inherit differences in client protein selectivity of the two isoforms
especially during stress conditions [27]. Herein, we report our work in the application of virtual
high-throughput screening and binding experiments, a strategy that we have previously used to
discover Hsp90 NTD inhibitors [66], to identify novel isoform-selective ligands for MD of Hsp90β.
Our report provides novel scaffolds for future development of isoform-selective Hsp90β MD inhibitors.
2. Results and Discussion
We first investigated potential binding pockets on the MD of Hsp90β that could be targeted by
small-molecule ligands. Unlike the NTD and CTD of Hsp90, the MD does not have a well-defined
binding site for small molecule ligands. We therefore performed blind docking experiments to predict
the most probable binding site for small molecule ligands [67,68]. Gambogic acid, an isoform-selective
inhibitor of the MD of Hsp90β [55], was used as the model ligand, and the crystal structure of the MD
of human Hsp90β (PDB ID: 3PRY, resolution 2.28 Å) was used as the target. Eighty-seven different
potential binding sites on Hsp90β were evaluated by using a consensus scoring approach [69,70] that
is based on four different scoring functions, GoldScore (GS) [71], ChemScore (CS) [72,73], piecewise
linear potential (ChemPLP) [74], and Astex Statistical Potential (ASP) [75] (Table S2). Our docking
results revealed a site within a 10 Å radius centring around the oxygen atom on the sidechain of
Asp-367 (x = 8.806, y = 23.993, z = 27.785; Figure S1) as the most probable pocket that could be targeted
by small molecules. The binding pocket that we identified is consistent with previous molecular
modelling work that suggested the region consisting of residues 350 to 436 as the potential binding site
for gambogic acid [55].
High-throughput virtual screening was then conducted against the identified binding site. In total,
9051 molecular entities were downloaded from the natural product library from the InterBioScreen Ltd
collection. Ten docking runs were carried out for each ligand with 30% search efficiency. From the
consensus scoring, all ligands with low CS (<15.0), GS (<51.0), ChemPLP (<55.0), and ASP (<25.2)
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scores, as well as those with limited hydrogen bonding (HB < 1) were eliminated in the initial screen.
913 candidates remained, and they were screened again with 100% default search efficiency and 50
genetic algorithm (GA) runs. The candidates with low scores on CS (<20.0), GS (<60.0), ChemPLP
(<60.0), ASP (<25.0), and HB (<1) were then filtered out, resulting in 152 compounds. The 152 candidate
compounds all have docking scores higher than the score that we obtained by docking gambogic acid to
Hsp90β. Visual inspection was then conducted for consensus of the best predicted configuration of the
ligands between each scoring function. Ligands that showed implausible configurations, i.e., those that
are strained, with lipophilic moieties pointing towards aqueous environment, and those that contain
undesirable moieties (e.g., those that are linked to cell toxicity and chemical reactivity), were eliminated.
As a result of virtual screening, 24 hit compounds (Figure 1 and Table S3) were selected for further
experimental testing against recombinant human Hsp90α MD (residues 294 to 554, Table S4) and
human Hsp90β MD (residues 286 to 546, Table S5). As there are tryptophan residues located within
the defined binding pocket in both Hsp90α MD and Hsp90β MD, intrinsic tryptophan fluorescence
quenching experiment was used to screen the binding of our virtual hits to the proteins. Initial
screening experiments were conducted by using 20 µM of Hsp90α/β MD and 1 mM of compounds.
Molecules that gave less than 40% fluorescence quenching were eliminated. Our results revealed that
eight compounds (5, 8, 9, 12, 17, 22, 24) bind to both Hsp90α MD and Hsp90β MD. In addition, one
compound (10) was found to induce significant quenching (~90%) of Hsp90β MD but not with Hsp90α
MD (~20%) (Figure 1, Table S6, and Figure S2).
We then focussed on studying the binding of our compounds (5, 8, 9, 10, 12, 17, 22, 24) to both
Hsp90α MD and Hsp90β MD. Titration experiments were performed to quantify the binding affinity
(dissociation constant, KD) to Hsp90α MD and Hsp90β MD (Table 1 and Figures S3–S10). The KD
values of gambogic acid were also measured as control (Table 1 and Figure S11). Our results show that
compounds 5, 9, 10, 12, 17, and 24 bind stronger to Hsp90β MD than to Hsp90α MD. The strongest
binder was 12, which binds to Hsp90β MD with a KD value of < 20 µM, and a KD value of 92 ± 0.8 µM
to Hsp90α MD. The seven-fold preference for the β-isoform is similar to gambogic acid, which has a KD
value of 195 ± 5 µM with Hsp90α MD, and a KD value of 33 ± 2 µM with Hsp90β MD. Our KD values
for gambogic acid are in agreement with previous studies (~10-fold preference) [55]. The selectivity for
the β-isoform (over α-isoforms) was progressively less for weaker binders. For example, compound 9,
which bind Hsp90β MD with a KD value of 57 ± 1 µM, only shows a 5-fold selectivity for Hsp90β
MD. The selectivity of compound 5, a structure analogue of compound 9 that binds Hsp90β MD with
a KD of 136 ± 1 µM, was found to be ~3-fold. Compounds 10, 17, and 24 (which bind Hsp90β MD
with KD values > 100 µM) only show ~2- to 3-fold preference for the β-isoform. Compounds 8 and 22,
which bind Hsp90β MD with KD > 500 µM, actually have a slight preference for Hsp90α MD, with KD
values of 284 ± 4 µM and 459 ± 7 µM, respectively.
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Table 1. Binding affinity (KD) of our compounds to Hsp90α/βMD. Gambogic acid was used as a control.
Compound KD to Hsp90α MD/µM KD to Hsp90β MD/µM
5 470 ± 2 136 ± 1
8 284 ± 4 500
9 299 ± 3 57 ± 1
10 >500 164 ± 2
12 92 ± 0.8 <20
17 506 ± 4 285 ± 8
22 459 ± 7 >500
24 661 ± 3 265 ± 4
Gambogic acid 195 ± 5 33 ± 2
Molecular docking of compounds 5, 8, 9, 10, 12, 17, 22, and 24 were then conducted to predict the
binding modes and relative energies of the compounds to the two isoforms of Hsp90 MD. The same
four scoring functions (ChemPLP, GS, CS, and ASP) were used. For example, with compound 12, our
docking results showed that the compounds bind to different part of the equivalent binding site (10 Å
radius from residue Glu-375 for Hsp90αMD (PDB id: 3Q6M; x = −1.652, y = −64.237, z = 27.08) and
residue Asp-367 for Hsp90β MD; Figure S1) on the two isoforms (Figure 2). The scale of the fitness
scores derived from the docking algorithms showed that all eight compounds have higher scores and
more hydrogen bonding interactions towards the binding pocket of Hsp90β MD when compared to the
docking results to Hsp90α-MD (Table S7; Figure 3 and Figures S12–S18). For example, for compound
12, the GS scoring function suggested that it does not have any hydrogen bonding interactions with
the neighbouring amino acid residues of Hsp90α MD, but it forms three different hydrogen bonds
with Hsp90β MD (Figure 3). The ligand binding positions that are generated by the search algorithm
component of molecular docking showed that the most likely binding pose of each compound has the
better fitness for the β-isoform than the α-isoform. These computational results correlate well with
the experimental trend of KD values for compounds 5, 9, 10, 12, 17, and 24 from the binding assay.
For compounds 8 and 22, the differences could be due to inaccuracies in the predicted binding modes
to the “real” configurations. Further studies, including competition binding experiments and protein
X-ray crystallography, may give more information about the interactions of these two molecules to
Hsp90 MD.
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Figure 2. Docking of compound 12 to (a) Hsp90α MD (PDB ID: 3Q6M) binding pocket (10 Å around
Glu-375) and to (b) Hsp90β MD (PDB id: 3PRY) binding pocket (10 Å around Asp-367). For aesthetic
reason, residues 359–492 and 350–484 were shown for Hsp90α and Hsp90β, respectively. Both of the
displays were processed from the ligand poses as predicted by the GoldScore (GS) scoring function.
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To check for the compatibility of the ligands with biological systems, their physicochemical
properties were derived. The calculated molecular descriptors for the eight derivatives were molecular
weight (MW), lipophilicity (logP), number of hydrogen bond donor (HD), number of hydrogen bond
acceptor (HA), polar surface area (PSA), and nu ber of rotatable bonds (RB), and are displayed in
Table 2. For MW, the values span from lead-like, through drug-like space to known drug space (KDS;
see Table 3 for definitions) [76–78]. HD for most compounds fit within the lead-like space [76,77].
The log P values lie in the range of 0.8 and 4.3 and the PSA values range from 91.2 to 153.9, with the
latter reaching into KDS [78].
The Known Drug Indexes 2a and 2b (KDI2a/2b) [79] were also derived. The KDI reflect the overall
balance of the molecular properties of ligands based on KDS. KDI2a is additive with a maximum of
6.0 and for KDI2b the indexes are multiplied giving 1.0 as its maximum. The average for KDI2a for
known drugs is 4.08 (± 1.27) and the ligands lie in the range of 3.63 to 5.68, i.e., they are well balanced
compared to known drugs, except for ligand 17, which has a large MW resulting in a low index.
The KDI2b gives a range of 0.02 to 0.70 with the average of know drugs being 0.18 (± 0.20), with ligands
12 and 22 with excellent values of 0.70. In general, the ligands are well balanced, with the notable
exception of 17, and can therefore be considered excellent starting points for further development.
Table 2. Molecular descriptors of the hit compounds.
Compound MW HD HA Log P PSA RB KDI2a/b
5 409.4 1.25 7 3.3 127.0 8 5.48/0.57
8 445.4 0.25 6.5 4.3 137.3 6 5.27/0.45
9 423.5 1.25 7 3.7 122.5 8 5.46/0.56
10 447.5 2 8.3 3.8 73.9 7 5.54/0.61
12 292.3 1 6.75 1.3 93.2 4 5.66/0.70
17 527.5 4 14.05 0.8 154.0 8 3.63/0.02
22 359.4 1.25 6 3.8 91.2 8 5.68/0.70
24 488.5 3 6.5 3.4 95.6 7 5.48/0.57
3. Materials and Methods
3.1. Recombinant Production of Hsp90α/βMD
Plasmids pET-21a encoding Hsp90α/β MD were purchased from GenScript (Central, Hong Kong.
For sequence, see Tables S3 and S4), which were then transformed into Escherichia coli BL21 (DE3)
for protein production. In brief, cells were first grown in 2-YT media to an optical density at
600 nm wavelength (OD600) of around 0.6 to 0.8. Protein production was then induced by the
addition of 0.2 mM isopropyl-1-thio-D-galactopyranoside (IPTG), which was then further incubated at
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15 ◦C overnight. The harvested cells were resuspended in 25 mM Tris (pH 8.0) supplemented with
Protease Inhibitor Cocktail (Abcam, Melbourne, Australia), 5 mM dithiothreitol (DTT), and 2 mM
ethylenediaminetetraacetic acid (EDTA). The resuspended cells were lysed by sonication. The filtered
cell lysate was applied to 1 mL HiTrap Q FF anion exchange chromatography column (GE Healthcare
Life Sciences, Auckland, New Zealand) equilibrated with 25 mM Tris (pH 8.0), 2 mM EDTA, and 2 mM
DTT. The protein was eluted with a linear gradient to 1 M NaCl from 0% to 100% over 70 min at a flow
rate of 1 mL min−1. The protein was further purified by HiPrep 16/60 Sephacryl S-100 HR gel filtration
column (GE Healthcare Life Sciences, Auckland, New Zealand) in 20 mM Tris (pH 7.5), 0.2 M KCl,
2 mM EDTA, and 2 mM DTT. The protein was then concentrated using Amicon Ultra-4 10K centrifugal
filter (Merck Millipore, Auckland, New Zealand) and stored at −80 ◦C until use.
3.2. Molecular Docking
A blind docking of gambogic acid was conducted over the entire MD of Hsp90β and a binding
pocket within a region consisted of residues 350 to 436 was identified. In order to validate the binding
site as reported, gambogic acid was docked to the crystal structure of the MD of human Hsp90β (PDB
id: 3PRY, resolution 2.28 Å) which was acquired from the Protein Data Bank (PDB) [80]. GS, CS,
ChemPLP, and ASP scoring functions were used to validate the predicted binding modes and relative
energies of the ligands using the GOLD v5.4 software suite. The Scigress Ultra v2.6 program (Version
FJ 2.6 (EU 3.1.7), Fujitsu Limited, Wellington, New Zealand) was used to prepare the crystal structure
as a docking scaffold, by adding hydrogen atoms and removing crystallographic water molecules.
The basic amino acids lysine and arginine were defined as protonated. Furthermore, aspartic and
glutamic acids were assumed deprotonated. The Scigress software suite was also used for structural
optimization of the ligands via MM2 force field method [81]. Scores and root-mean-square deviation
(RMSD) between the predicted ligand conformation of the scoring functions were compared to define
the centre of binding pocket.
3.3. Pilot Screening
GOLD v5.4 software suite was used for virtual screening. Full experimental details were reported
in Section 2.
3.4. Calculation of Molecular Descriptors
QikProp 3.2 software package (Schrödinger, New York, NY, USA) was used to calculate the
molecular descriptors, which are the numerical values that assesses the properties of the compounds.
The criterion of lead-like, drug-like, and KDS are listed in terms of the six respective molecular
descriptors in Table 3 [76–78]. The reliability of QikProp is established for the calculated descriptors [82].
Table 3. Definition of lead-like, drug-like, and known drug space (KDS). The values given are the
maximum value for each descriptor.
Molecular Descriptors Lead-Like Space Drug-Like Space Known Drug Space
MW (g·mol−1) 300 500 800
Log p 3 5 6.5
HD 3 5 7
HA 3 10 15
PSA (Å2) 60 140 180
RB 3 10 17
3.5. Intrinsic Tryptophan Fluorescence Spectroscopy
Fluorescence was measured using EnSpire Multimode Plate Reader (PerkinElmer, Melbourne,
Australia). Experiments were performed in 20 µM of Hsp90 MD in 20 mM Tris (pH 7.5) and 0.2 M KCl.
Different concentration of the virtual hits (InterBioScreen, Bar, Montenegro) or gambogic acid were
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added to the mixture. Excitation wavelength was 280 nm and intrinsic fluorescence was measured
between 300 and 450 nm. The control experiment with Hsp90 MD on its own was conducted.
Background fluorescence arising from the compound was subtracted to generate the final spectrum.
The total volume per well of the 96-well microplate was 30 µL. Non-linear curve fitting of Equation (1)
to the data was conducted using SigmaPlot 14.0 (Systat Software, San Jose, CA, USA). All tests were
conducted in triplicate and the errors shown are standard deviation. KD was calculated for each binder
using Equation (1), where ∆obs is the changes in fluorescence intensity from the titrations, ∆max is the
maximum fluorescence intensity change, [LT] represents the titrated ligand concentration, and [PT]
indicates the protein concentration.
∆obs = ∆max ×
(KD + [LT] + [PT]) −
√
(KD + [LT] + [PT])
2 − (4× [PT] × [LT])
2× [PT] (1)
4. Conclusions
Overall, by using an approach that combines both virtual screening and binding studies, we
have successfully identified novel ligands that are selective for the β-isoform of Hsp90 MD. Molecular
modelling was used to predict the most probable binding modes of the compounds to Hsp90 MD
and intrinsic protein fluorescence was used to measure the binding affinity of our compounds to both
isoforms of Hsp90 MD. Although the binding affinity and selectivity of the ligands for the β-isoform
appears to be modest (low µM KD values, ~5 to 7-fold for the best compounds), this is on par with
a previous study that reported selective Hsp90β MD inhibitor (gambogic acid, low µM KD value,
and ~7-fold preference in terms of KD) [55]. In addition, in a recent study by Khandelwal et al., who
reported selective inhibitors for Hsp90β NTD, their initial hits only showed 2–4-fold selectivity [62].
As all of our compounds fit into the known-drug space, drug-like space, or lead-like space areas,
we believe our compounds are therefore good starting points for further developments of more selective
Hsp90β MD inhibitors.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/21/
5333/s1.
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ASP Astex Statistical Potential
ATP Adenosine triphosphate







HA Number of hydrogen bond acceptor
HD Number of hydrogen bond donor
Hsp90 Heat shock protein 90
IPTG Isopropyl-1-thio-D-galactopyranoside
KD Dissociation constant
KDI Known drug index





OD600 Optical density at 600 nm wavelength
PDB Protein data bank
PSA Polar surface area
RB Number of rotatable bonds
RMSD Root-mean-square deviation
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